-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Castle Biosciences, Raises Price Target to $43

Benzinga·01/05/2026 16:56:23
语音播报
Guggenheim analyst Subbu Nambi maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $30 to $43.